Advertisement
UK markets closed

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • FTSE 250

    20,164.54
    +112.21 (+0.56%)
     

  • AIM

    771.53
    +3.42 (+0.45%)
     

  • GBP/EUR

    1.1652
    -0.0031 (-0.26%)
     

  • GBP/USD

    1.2546
    +0.0013 (+0.11%)
     

  • Bitcoin GBP

    50,009.98
    +2,242.62 (+4.69%)
     

  • CMC Crypto 200

    1,359.39
    +82.41 (+6.45%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +450.02 (+1.18%)
     

  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     

  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • HANG SENG

    18,475.92
    +268.79 (+1.48%)
     

  • DAX

    18,001.60
    +105.10 (+0.59%)
     

  • CAC 40

    7,957.57
    +42.92 (+0.54%)
     
MONEY:

Best savings accounts that offer above inflation rates

Where to find a top-rated deal that works for you

AstraZeneca buys oncology-focused Spirogen for up to $440 mln

Reuters - UK Focus

LONDON, Oct (KOSDAQ: 039200.KQ - news) 15 (Reuters) - British drugmaker AstraZeneca (LSE: AZN.L - news) said on Tuesday its MedImmune unit would buy biotech company Spirogen for up to $440 million to bolster its research and development pipeline in oncology.

Privately held Spirogen focuses on antibody-drug conjugate technology, which has the potential to directly target cancer tumours while safeguarding healthy cells, AstraZeneca (NYSE: AZN - news) said.

AstraZeneca said it would pay an initial $200 million plus a further $240 million if Spirogen meets development targets.

It will also pay $20 million to take an equity investment in Swiss-based ADC Therapeutics, which has a licensing agreement with Spirogen.

ADVERTISEMENT

"The cutting-edge technologies developed by Spirogen and ADC Therapeutics complement MedImmune's innovative antibody engineering capabilities, enabling us to accelerate antibody-drug conjugates into the clinic," said MedImmune Executive Vice President Bahija Jallal.

Oncology treatments, both traditional "small cell" pills and injectable biologics, has been prioritised as a research area by AstraZeneca Chief Executive Pascal Soriot, who used to head Roche's Genentech biotech unit.

MedImmume, the U.S. biotech business that AstraZeneca bought in 2007 for $15.6 billion, is key to the strategy.

The unit is focused on two key areas in oncology development: antibody-drug conjugates and immune-mediated cancer therapy, which aims to harness the power of the patient's own immune system to fight cancer.